De Novo Classification Services

Bringing a novel medical device to the United States market is a complex, high-stakes milestone. For innovative technologies lacking a legally marketed predicate device, the Medical Device De Novo Classification pathway is required. While this pathway may grant your product a unique competitive advantage as a brand-new device category, it also demands rigorous clinical and technical evidence to prove a low-to-moderate risk profile without a comparative baseline.

FDA Quality and Regulatory Consultants (FDAQRC) provides trusted De Novo classification services to help your business overcome regulatory uncertainty, mitigate costly market delays and navigate FDA authorization.

Expert Solutions for the FDA De Novo Pathway

At FDAQRC, our De Novo classification consulting services equip organizations with strategic oversight to navigate FDA requirements. We operate as an extension of your internal team, helping you transition your novel technology from development into an authorized commercial product.

Pre-Submission Strategy and Pathway Alignment

Determining whether a novel device qualifies for the De Novo pathway rather than a 510(k) or Premarket Approval (PMA) can be a resource-intensive, uncertain process. Misaligning your regulatory strategy early on frequently leads to costly FDA rejections and derailed launch timelines.

Proactive alignment is a critical defense against agency pushback. Our specialists evaluate your technology to justify De Novo eligibility and spearhead crucial FDA pre-submission (Q-Sub) meetings. We help you negotiate data requirements up front and define necessary special controls to securely prepare De Novo request strategies.

Clinical Data Assurance and Evidence Generation

Without a legally marketed predicate to rely on, your clinical data must stand on its own to prove the device’s safety and effectiveness. Designing and executing these complex, first-in-class trials often drains internal bandwidth and exposes your organization to timeline setbacks if data integrity is not maintained. Our specialized auditors deliver proactive assessments of your investigator sites and trial master files. We actively enforce Good Clinical Practice (GCP) compliance throughout the trial life cycle, helping your organization generate the high-quality evidence necessary to satisfy strict FDA scrutiny.

FDA De Novo Submission Preparation

The sheer volume of technical, clinical and administrative documentation required for a novel device demands significant internal bandwidth. Navigating this highly complex assembly process heightens the risk of a Refuse to Accept (RTA) decision if critical details are overlooked. We manage the complete FDA De Novo submission to alleviate your internal workload. Leveraging the expertise of seasoned industry experts, we meticulously assemble, review and optimize your comprehensive dossier to accelerate agency review timelines.

QMS Optimization and Audit Readiness

A first-of-its-kind classification often introduces unique postmarket requirements and special controls. Seamlessly integrating these unprecedented mandates into your existing Quality Management System (QMS) requires rigorous precision to avoid future compliance gaps. We conduct targeted gap analyses to assess your QMS against FDA 21 CFR Part 820 standards. We implement long-term remediation plans, guide Corrective and Preventive Actions (CAPA) management and provide teamwide inspection readiness through meticulous mock audits.

Why Partner With FDAQRC for De Novo Consulting

Pioneering a new medical device category requires more than standard regulatory support — it demands strategic foresight and authoritative FDA experience. FDAQRC provides white-glove consulting solutions designed to navigate the unique pressures of the De Novo pathway.

When you partner with our team, you gain:

  • Deep regulatory expertise: Negotiating a novel classification requires understanding how the agency evaluates unprecedented technologies. Our experts have extensive experience dealing with FDA regulatory requirements and bringing strategic insight to our partnerships.
  • Concierge-level project management: To protect your internal bandwidth, we assign your company a dedicated project manager. From coordinating complex technical resources to driving strict submission timelines, we handle the administrative heavy lifting, allowing your team to focus on commercialization.
  • Sustainable commercial compliance: Securing your initial FDA authorization is only the first step. We look beyond the immediate submission to build a resilient regulatory foundation. Our approach establishes robust, scalable quality systems that support your device throughout its commercial life cycle.

Take the Next Step Toward FDA Authorization

Build a data-driven case for your innovation and expedite your path to the U.S. market with FDAQRC. Submit our online form to book your consultation.

Request a Consultation